Literature DB >> 31912252

Risk Factors for Occult Lymph Node Metastasis in Peripheral Non-Small Cell Lung Cancer with Invasive Component Size 3 cm or Less.

Youngkyu Moon1, Si Young Choi2, Jae Kil Park3, Kyo Young Lee4.   

Abstract

BACKGROUND: In the seventh edition TNM staging system for lung cancer, a high maximum standardized uptake value (SUVmax) on positron emission tomography was regarded as a risk factor for occult lymph node metastasis in clinical T1N0 non-small cell lung cancer (NSCLC). However, in the eighth edition TNM classification, tumors are classified according to the size of the invasive component only, and those with invasive component size ≤3 cm are diagnosed as stage T1. The aim of this study was to reassess the risk factors for occult lymph node metastasis under the eighth edition TNM classification for lung cancer.
METHODS: From 2010 to 2017, 553 patients with clinical N0 peripheral NSCLC with invasive component size ≤3 cm underwent anatomical lobectomy with systematic lymph node dissection. We analyzed these cases retrospectively to identify risk factors for postoperative nodal upstaging.
RESULTS: Among 553 study patients, 54 (9.8%) had nodal upstaging after surgery. In multivariate analysis adopting the eighth edition TNM classification for lung cancer, serum carcinoembryonic antigen (CEA) level (hazard ratio [HR] = 1.113, p = 0.002), invasive component size (HR = 2.398, p = 0.004), visceral pleural invasion (HR = 2.901, p = 0.005), and lymphatic invasion (HR = 9.336, p < 0.001) were significant risk factors for nodal upstaging, but SUVmax was not.
CONCLUSION: SUVmax is not a predictor of nodal upstaging in clinical N0 peripheral NSCLC with invasive component size ≤3 cm under the eighth edition TNM classification for lung cancer. Significant risk factors of occult lymph node metastasis are serum CEA level, tumor invasive component size, visceral pleural invasion, and lymphatic invasion.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31912252     DOI: 10.1007/s00268-019-05365-5

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  23 in total

1.  Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Authors:  Ramón Rami-Porta; Hisao Asamura; William D Travis; Valerie W Rusch
Journal:  CA Cancer J Clin       Date:  2017-01-31       Impact factor: 508.702

2.  Lobe-Specific Nodal Dissection for Clinical Stage I and II NSCLC: Japanese Multi-Institutional Retrospective Study Using a Propensity Score Analysis.

Authors:  Tomoyuki Hishida; Etsuo Miyaoka; Kohei Yokoi; Masahiro Tsuboi; Hisao Asamura; Katsuyuki Kiura; Kazuhisa Takahashi; Hirotoshi Dosaka-Akita; Hideo Kobayashi; Hiroshi Date; Hirohito Tada; Meinoshin Okumura; Ichiro Yoshino
Journal:  J Thorac Oncol       Date:  2016-05-29       Impact factor: 15.609

3.  The effectiveness of mediastinal lymph node evaluation in a patient with ground glass opacity tumor.

Authors:  Youngkyu Moon; Sook Whan Sung; Min Namkoong; Jae Kil Park
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

4.  The role of (18)F-FDG PET/CT for evaluation of metastatic mediastinal lymph nodes in patients with lung squamous-cell carcinoma or adenocarcinoma.

Authors:  Peiou Lu; Yajuan Sun; Yanqin Sun; Lijuan Yu
Journal:  Lung Cancer       Date:  2014-04-18       Impact factor: 5.705

5.  Lobe-Specific Lymph Node Dissection as a Standard Procedure in Surgery for Non-Small Cell Lung Cancer: A Propensity Score Matching Study.

Authors:  Hiroyuki Adachi; Kentaro Sakamaki; Teppei Nishii; Taketsugu Yamamoto; Takuya Nagashima; Yoshihiro Ishikawa; Kohei Ando; Kazuki Yamanaka; Katsuya Watanabe; Yutaka Kumakiri; Masahiro Tsuboi; Takamitsu Maehara; Haruhiko Nakayama; Munetaka Masuda
Journal:  J Thorac Oncol       Date:  2016-08-20       Impact factor: 15.609

6.  Clinical Predictors of Nodal Metastases in Peripherally Clinical T1a N0 Non-Small Cell Lung Cancer.

Authors:  Galal Ghaly; Mohamed Rahouma; Mohamed K Kamel; Abu Nasar; Sebron Harrison; Andrew B Nguyen; Jeffrey Port; Brendon M Stiles; Nasser K Altorki; Paul C Lee
Journal:  Ann Thorac Surg       Date:  2017-05-24       Impact factor: 4.330

Review 7.  Complete resection in lung cancer surgery: proposed definition.

Authors:  Ramón Rami-Porta; Christian Wittekind; Peter Goldstraw
Journal:  Lung Cancer       Date:  2005-07       Impact factor: 5.705

8.  Optimal Lymph Node Examination and Adjuvant Chemotherapy for Stage I Lung Cancer.

Authors:  Jie Dai; Ming Liu; Yang Yang; Qiuyuan Li; Nan Song; Gaetano Rocco; Alan D L Sihoe; Diego Gonzalez-Rivas; Hon Chi Suen; Wenxin He; Liang Duan; Jiang Fan; Deping Zhao; Haifeng Wang; Yuming Zhu; Chang Chen; Robert B Diasio; Gening Jiang; Ping Yang; Peng Zhang
Journal:  J Thorac Oncol       Date:  2019-04-19       Impact factor: 15.609

9.  Clinicopathologic Factors Associated With Occult Lymph Node Metastasis in Patients With Clinically Diagnosed N0 Lung Adenocarcinoma.

Authors:  Youngkyu Moon; Kyung Soo Kim; Kyo Young Lee; Sook Whan Sung; Young Kyoon Kim; Jae Kil Park
Journal:  Ann Thorac Surg       Date:  2016-03-05       Impact factor: 4.330

10.  Consolidation/Tumor Ratio on Chest Computed Tomography as Predictor of Postoperative Nodal Upstaging in Clinical T1N0 Lung Cancer.

Authors:  Youngkyu Moon; Jae Kil Park; Kyo Young Lee; Min Namkoong; Seha Ahn
Journal:  World J Surg       Date:  2018-09       Impact factor: 3.352

View more
  8 in total

1.  Clinicopathological models for predicting lymph node metastasis in patients with early-stage lung adenocarcinoma: the application of machine learning algorithms.

Authors:  Yuming Chong; Yijun Wu; Jianghao Liu; Chang Han; Liang Gong; Xinyu Liu; Naixin Liang; Shanqing Li
Journal:  J Thorac Dis       Date:  2021-07       Impact factor: 2.895

2.  Is the size of the lepidic component negligible when measuring the size of the tumor to determine the stage of lung adenocarcinoma?

Authors:  Youngkyu Moon
Journal:  J Thorac Dis       Date:  2021-03       Impact factor: 2.895

3.  Video-assisted thoracoscopic lobectomy versus open lobectomy in the treatment of large lung cancer: propensity-score matched analysis.

Authors:  Jeonghee Yun; Junghee Lee; Sumin Shin; Hong Kwan Kim; Yong Soo Choi; Jhingook Kim; Jae Il Zo; Young Mog Shim; Jong Ho Cho
Journal:  J Cardiothorac Surg       Date:  2022-01-08       Impact factor: 1.637

4.  A Radiomics Nomogram for Preoperative Prediction of Clinical Occult Lymph Node Metastasis in cT1-2N0M0 Solid Lung Adenocarcinoma.

Authors:  Ran Zhang; Ranran Zhang; Ting Luan; Biwei Liu; Yimei Zhang; Yaping Xu; Xiaorong Sun; Ligang Xing
Journal:  Cancer Manag Res       Date:  2021-10-28       Impact factor: 3.989

5.  Factors Associated with Nodal Upstaging in Clinical T1a-bN0M0 Non-Small Cell Lung Cancers.

Authors:  Tung-Ming Tsai; Chao-Yu Liu; Mong-Wei Lin; Hsao-Hsun Hsu; Jin-Shing Chen
Journal:  Cancers (Basel)       Date:  2022-03-01       Impact factor: 6.639

6.  Preoperative risk factors of lymph node metastasis in clinical N0 lung adenocarcinoma of 3 cm or less in diameter.

Authors:  Cheng Fang; Yangwei Xiang; Weili Han
Journal:  BMC Surg       Date:  2022-04-29       Impact factor: 2.030

7.  Genomics Analysis and Nomogram Risk Prediction of Occult Lymph Node Metastasis in Non-Predominant Micropapillary Component of Lung Adenocarcinoma Measuring ≤ 3 cm.

Authors:  Kun Wang; Mengchao Xue; Jianhao Qiu; Ling Liu; Yueyao Wang; Rongyang Li; Chenghao Qu; Weiming Yue; Hui Tian
Journal:  Front Oncol       Date:  2022-07-13       Impact factor: 5.738

8.  The value of pulmonary nodule diameter and consolidation/tumor rate in the prediction of lymph node metastasis in early-stage (cT1N0M0) lung adenocarcinoma.

Authors:  Weipeng Shao; Zhaohua Zhang; Zhan Liu; Zhenrong Zhang; Hongliang Sun; Xiaowei Wang; Hongxiang Feng; Chaoyang Liang; Deruo Liu
Journal:  Transl Cancer Res       Date:  2021-01       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.